• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

生物标志物的随访能更好地预测COVID-19患者的不良预后。

The Follow-Up of Biomarkers Better Predicts the Poor Outcome in COVID-19 Patients.

作者信息

Basoglu Ozen K, Ozhan Mustafa Hikmet, Ekren Pervin Korkmaz, Ak Gunes, Tasbakan Mehmet Sezai, Sayiner Abdullah

机构信息

Department of Chest Diseases, Ege University Faculty of Medicine

Department of Chest Diseases, Ege University Faculty of Medicine.

出版信息

Ann Clin Lab Sci. 2020 Nov;50(6):848-851.

PMID:33334804
Abstract

OBJECTIVE

To investigate the course of biomarkers on admission and follow-up in order to identify early predictors for poor outcome in COVID-19 patients.

METHODS

In this study, 132 COVID-19 patients were classified as good outcome (n=62) and poor outcome (n=70) groups. Laboratory parameters were evaluated on admission and within 5-7 days after hospitalization.

RESULTS

Baseline levels of neutrophil-lymphocyte ratio, CRP, procalcitonin, ferritin, D-dimer and LDH were higher (<0.01); lymphocyte count was lower in the poor outcome patients. During follow-up there was a larger decrease in lymphocyte count and more prominent increases in other biomarkers (<0.001). In ROC analysis, the AUCs strongly indicated the poor outcome on days 5-7 of the hospitalization.

CONCLUSIONS

This study suggests that the follow-up measurements of the biomarkers better predict the poor outcome in COVID-19 pneumonia.

摘要

目的

研究入院时及随访期间生物标志物的变化过程,以确定新冠病毒疾病(COVID-19)患者不良预后的早期预测指标。

方法

在本研究中,132例COVID-19患者被分为预后良好组(n = 62)和预后不良组(n = 70)。在入院时及住院后5 - 7天评估实验室参数。

结果

预后不良患者的中性粒细胞与淋巴细胞比值、CRP、降钙素原、铁蛋白、D - 二聚体和乳酸脱氢酶的基线水平较高(<0.01);淋巴细胞计数较低。在随访期间,淋巴细胞计数下降幅度更大,其他生物标志物升高更显著(<0.001)。在ROC分析中,曲线下面积(AUC)强烈表明在住院第5 - 7天时预后不良。

结论

本研究表明,对生物标志物进行随访测量能更好地预测COVID-19肺炎的不良预后。

相似文献

1
The Follow-Up of Biomarkers Better Predicts the Poor Outcome in COVID-19 Patients.生物标志物的随访能更好地预测COVID-19患者的不良预后。
Ann Clin Lab Sci. 2020 Nov;50(6):848-851.
2
Diagnostic yield of bacteriological tests and predictors of severe outcome in adult patients with COVID-19 presenting to the emergency department.在因 COVID-19 而到急诊科就诊的成年患者中,细菌学检测的诊断效果及其导致重症的预测因子。
Emerg Med J. 2021 Sep;38(9):685-691. doi: 10.1136/emermed-2020-211027. Epub 2021 Jul 21.
3
Utility of inflammatory biomarkers in patients with COVID-19 infections: Bahrain experience.炎症生物标志物在 COVID-19 感染患者中的应用:巴林经验。
Biomark Med. 2021 Jun;15(8):541-549. doi: 10.2217/bmm-2020-0422. Epub 2021 May 14.
4
The clinical implication of dynamic neutrophil to lymphocyte ratio and D-dimer in COVID-19: A retrospective study in Suzhou China.新冠肺炎患者中性粒细胞与淋巴细胞比值和 D-二聚体的临床意义:中国苏州的一项回顾性研究。
Thromb Res. 2020 Aug;192:3-8. doi: 10.1016/j.thromres.2020.05.006. Epub 2020 May 6.
5
Correlation between laboratory parameters on admission and outcome of COVID-19 in maintenance hemodialysis patients.维持性血液透析患者入院时实验室参数与 COVID-19 结局的相关性。
Int Urol Nephrol. 2021 Jan;53(1):165-169. doi: 10.1007/s11255-020-02646-0. Epub 2020 Sep 20.
6
Predicting Disease Severity and Outcome in COVID-19 Patients: A Review of Multiple Biomarkers.预测 COVID-19 患者的疾病严重程度和结局:多种生物标志物的综述。
Arch Pathol Lab Med. 2020 Dec 1;144(12):1465-1474. doi: 10.5858/arpa.2020-0471-SA.
7
Combined lymphocyte/monocyte count, D-dimer and iron status predict COVID-19 course and outcome in a long-term care facility.联合淋巴细胞/单核细胞计数、D-二聚体和铁状态可预测长期护理机构中 COVID-19 的病程和结局。
J Transl Med. 2021 Feb 17;19(1):79. doi: 10.1186/s12967-021-02744-2.
8
Usefulness of biological markers in the early prediction of corona virus disease-2019 severity.生物标志物在预测 2019 年冠状病毒病严重程度中的作用。
Scand J Clin Lab Invest. 2020 Dec;80(8):611-618. doi: 10.1080/00365513.2020.1821396. Epub 2020 Sep 18.
9
Clinical, epidemiological, and laboratory characteristics of mild-to-moderate COVID-19 patients in Saudi Arabia: an observational cohort study.沙特阿拉伯轻度至中度 COVID-19 患者的临床、流行病学和实验室特征:一项观察性队列研究。
Eur J Med Res. 2020 Nov 25;25(1):61. doi: 10.1186/s40001-020-00462-x.
10
The poor prognosis and influencing factors of high D-dimer levels for COVID-19 patients.新冠肺炎患者高 D-二聚体水平的预后不良及其影响因素。
Sci Rep. 2021 Jan 19;11(1):1830. doi: 10.1038/s41598-021-81300-w.

引用本文的文献

1
Novel Biomarkers for SARS-CoV-2 Infection: A Systematic Review and Meta-Analysis.新型冠状病毒(SARS-CoV-2)感染的生物标志物:系统评价与荟萃分析
J Pers Med. 2025 Jun 1;15(6):225. doi: 10.3390/jpm15060225.
2
What is the Optimal Treatment Regimen of Low-MolecularWeight Heparin in Coronavirus Disease 2019 Pneumonia?2019冠状病毒病肺炎中低分子肝素的最佳治疗方案是什么?
Thorac Res Pract. 2023 Nov 16;25(1):5 - 10. doi: 10.5152/ThoracResPract.2023.23039.